Is CVS or VRTX cheaper?

On trailing earnings, VRTX is cheaper: CVS trades at a 44.92 P/E and VRTX at 26.39.

Which has grown faster, CVS or VRTX?

Over the past five years, VRTX grew revenue faster — CVS at a 8.52% CAGR versus VRTX at 13.82%.

Does CVS or VRTX pay a bigger dividend?

CVS pays a dividend (2.61% yield) while VRTX does not currently pay one.

Is CVS or VRTX more profitable?

VRTX runs the higher net margin — CVS at 0.72% versus VRTX at 35.40%.

Which has been the better investment, CVS or VRTX?

Over the past 10-year, VRTX delivered the higher annualized total return — CVS at 3.66% versus VRTX at 17.13%. Past performance doesn't predict future results.

CVS Health Corporation (CVS) vs Vertex Pharmaceuticals Incorporated (VRTX)

VRTX leads on 10 of 15 compared metrics.

A side-by-side comparison of CVS Health Corporation and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).

CVS

CVS Health Corporation

$130.09B

$101.96Healthcare

VRTX

Vertex Pharmaceuticals Incorporated

$112.92B

$444.93Healthcare

Total return — CVS vs VRTX

growth of $100 · last 30y

CVS +882.3%VRTX +2389.1%VRTX compounded faster

CVS VRTX

CVS vs VRTX: by the numbers

•CVS is the larger company ($130.09B vs $112.92B market cap).
•VRTX trades at the lower earnings multiple (26.39 vs 44.92 P/E).
•VRTX converts more revenue to profit (35.40% vs 0.72% net margin).
•VRTX grew revenue faster over the past five years (13.82% vs 8.52% CAGR).
•CVS pays a dividend (2.61% yield) while VRTX does not currently pay one.

Which is better, CVS or VRTX?

Metric tally: CVS 5 · VRTX 10

It depends on what you're optimizing for:

ValueVRTX(lower P/E)

GrowthVRTX(faster 5Y revenue CAGR)

QualityVRTX(higher ROIC)

Valuation

Metric	CVS	VRTX
P/E ratio	44.92	26.39●
Forward P/E	12.17●	20.58
P/S ratio	0.32●	9.31
P/B ratio	1.68●	5.89
PEG ratio	—	3.23
EV / EBITDA	17.90●	20.72
FCF yield	5.67%●	3.25%

Profitability

Metric	CVS	VRTX
Gross margin	13.87%	86.28%●
Operating margin	1.46%	38.97%●
Net margin	0.72%	35.40%●
ROE	3.79%	22.41%●
ROIC	4.72%	18.12%●

Dividends

Metric	CVS	VRTX
Dividend yield	2.61%	—
Payout ratio	190.00%	—

Growth (annualized)

Metric	CVS	VRTX
Revenue CAGR (5Y)	8.52%	13.82%●
EPS CAGR (5Y)	-23.89%	8.17%●
FCF CAGR (5Y)	-10.57%	4.01%●
Total return CAGR (5Y)	7.06%	18.17%●

Frequently asked

Which is better, CVS or VRTX?: It depends on your goal. value: VRTX (lower P/E); growth: VRTX (faster 5Y revenue CAGR); quality: VRTX (higher ROIC). Across all compared metrics, VRTX leads 10 to 5.
Is CVS or VRTX cheaper?: On trailing earnings, VRTX is cheaper: CVS trades at a 44.92 P/E and VRTX at 26.39.
Which has grown faster, CVS or VRTX?: Over the past five years, VRTX grew revenue faster — CVS at a 8.52% CAGR versus VRTX at 13.82%.
Does CVS or VRTX pay a bigger dividend?: CVS pays a dividend (2.61% yield) while VRTX does not currently pay one.
Is CVS or VRTX more profitable?: VRTX runs the higher net margin — CVS at 0.72% versus VRTX at 35.40%.
Which has been the better investment, CVS or VRTX?: Over the past 10-year, VRTX delivered the higher annualized total return — CVS at 3.66% versus VRTX at 17.13%. Past performance doesn't predict future results.

Go deeper

Full CVS analysis Full VRTX analysis Interactive comparison tool

Dig into the metrics

CVS Health P/E ratio Vertex Pharmaceuticals P/E ratio CVS Health dividend yield Vertex Pharmaceuticals dividend yield CVS Health ROE Vertex Pharmaceuticals ROE CVS Health operating margin Vertex Pharmaceuticals operating margin CVS Health revenue growth Vertex Pharmaceuticals revenue growth CVS Health free cash flow Vertex Pharmaceuticals free cash flow

CVS Health & Vertex Pharmaceuticals appear in these rankings

Highest Dividend Yield Stocks Highest ROIC Stocks Highest Operating Margin Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.